(Q36808054)

16 August 2017

1 reference

title

Aripiprazole: pharmacology and evidence in bipolar disorder (English)

1 reference

16 August 2017

1 reference

Joanna K Soczynska

2

0 references

Roger S McIntyre

1

object named as

Roger S McIntyre

1 reference

16 August 2017

author name string

Hanna O Woldeyohannes

3

1 reference

16 August 2017

Andrew Miranda

4

1 reference

16 August 2017

Jakub Z Konarski

5

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 May 2007

1 reference

Expert Opinion on Pharmacotherapy

16 August 2017

published in

1 reference

16 August 2017

volume

8

1 reference

16 August 2017

issue

7

1 reference

16 August 2017

page(s)

1001-1009

1 reference

Insurance expenditures on bipolar disorder: clinical and parity implications

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Aripiprazole: A New Atypical Antipsychotic Drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Double-blind comparison of the continued use of antipsychotic treatment versus its discontinuation in remitted manic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

Excess mortality in bipolar and unipolar disorder in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.7.1001

10.1517/14656566.8.7.1001

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference